These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 11519155)

  • 1. [Pharmacokinetics and drug interactions of antidepressive agents].
    Sawada Y; Ohtani H
    Nihon Rinsho; 2001 Aug; 59(8):1539-45. PubMed ID: 11519155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacokinetics and drug interaction of antidepressants and anti-manic drugs].
    Suzuki K; Koyama T
    Ryoikibetsu Shokogun Shirizu; 2003; (38):366-9. PubMed ID: 12877004
    [No Abstract]   [Full Text] [Related]  

  • 3. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
    Ball SE; Ahern D; Scatina J; Kao J
    Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of milnacipran in comparison with other antidepressants.
    Puozzo C; Leonard BE
    Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():15-27. PubMed ID: 8923123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications.
    Caccia S
    Clin Pharmacokinet; 1998 Apr; 34(4):281-302. PubMed ID: 9571301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.
    Ereshefsky L; Riesenman C; Lam YW
    Clin Pharmacokinet; 1995; 29 Suppl 1():10-8; discussion 18-9. PubMed ID: 8846618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reboxetine and cytochrome P450--comparison with paroxetine treatment in humans.
    Kuhn UD; Kirsch M; Merkel U; Eberhardt AM; Wenda B; Maurer I; Härtter S; Hiemke C; Volz HP; Balogh A
    Int J Clin Pharmacol Ther; 2007 Jan; 45(1):36-46. PubMed ID: 17256449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluvoxamine and tricyclic antidepressants (TCAs): how do the TCAs compare as "new" drugs with established fluvoxamine?
    Ashford JJ
    Int Clin Psychopharmacol; 1995 Jan; 9 Suppl 4():27-31. PubMed ID: 7622820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update.
    Spina E; Santoro V; D'Arrigo C
    Clin Ther; 2008 Jul; 30(7):1206-27. PubMed ID: 18691982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology and pharmacokinetics of milnacipran.
    Puozzo C; Panconi E; Deprez D
    Int Clin Psychopharmacol; 2002 Jun; 17 Suppl 1():S25-35. PubMed ID: 12369608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence.
    Sproule BA; Naranjo CA; Brenmer KE; Hassan PC
    Clin Pharmacokinet; 1997 Dec; 33(6):454-71. PubMed ID: 9435993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors.
    Baumann P
    Clin Pharmacokinet; 1996 Dec; 31(6):444-69. PubMed ID: 8968657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of chronic treatment with milnacipran on sleep architecture in rats compared with paroxetine and imipramine.
    Gervasoni D; Panconi E; Henninot V; Boissard R; Barbagli B; Fort P; Luppi PH
    Pharmacol Biochem Behav; 2002 Oct; 73(3):557-63. PubMed ID: 12151030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes.
    Crewe HK; Lennard MS; Tucker GT; Woods FR; Haddock RE
    Br J Clin Pharmacol; 1992 Sep; 34(3):262-5. PubMed ID: 1389951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.
    Preskorn SH
    Clin Pharmacokinet; 1997; 32 Suppl 1():1-21. PubMed ID: 9068931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro inhibition and induction of human liver cytochrome p450 enzymes by milnacipran.
    Paris BL; Ogilvie BW; Scheinkoenig JA; Ndikum-Moffor F; Gibson R; Parkinson A
    Drug Metab Dispos; 2009 Oct; 37(10):2045-54. PubMed ID: 19608694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants.
    von Moltke LL; Greenblatt DJ; Court MH; Duan SX; Harmatz JS; Shader RI
    J Clin Psychopharmacol; 1995 Apr; 15(2):125-31. PubMed ID: 7782485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview of the pharmacokinetics of fluvoxamine.
    van Harten J
    Clin Pharmacokinet; 1995; 29 Suppl 1():1-9. PubMed ID: 8846617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concomitant use of selective serotonin reuptake inhibitors with other cytochrome P450 2D6 or 3A4 metabolized medications: how often does it really happen?
    Gregor KJ; Way K; Young CH; James SP
    J Affect Disord; 1997 Oct; 46(1):59-67. PubMed ID: 9387087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are pharmacokinetic drug interactions with the SSRIs an issue?
    Brøsen K
    Int Clin Psychopharmacol; 1996 Mar; 11 Suppl 1():23-7. PubMed ID: 8732441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.